Comparative Pharmacology
Head-to-head clinical analysis: DARVOCET A500 versus Q GESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVOCET A500 versus Q GESIC.
DARVOCET A500 vs Q-GESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination analgesic: acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system; propoxyphene is a mu-opioid receptor agonist.
Q-GESIC is a centrally acting non-opioid analgesic; its exact mechanism is unknown but may involve inhibition of cyclooxygenase (COX) and modulation of descending serotonergic and noradrenergic pathways.
One tablet (500 mg acetaminophen, 100 mg propoxyphene napsylate) orally every 4 hours as needed for pain; maximum 6 tablets per day.
1-2 tablets (325-650 mg acetaminophen and 5-10 mg hydrocodone) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Propoxyphene: 6-12 hours (terminal, prolonged in elderly, hepatic impairment, or overdose). Acetaminophen: 2-3 hours (terminal, prolonged in hepatic impairment or overdose).
Terminal elimination half-life is 2-4 hours; clinical context: requires dosing every 4-6 hours for sustained analgesia.
Propoxyphene: ~20-25% renal as unchanged drug, ~35% as norpropoxyphene, ~20% biliary/fecal. Acetaminophen: ~2-4% renal unchanged, ~85% as glucuronide and sulfate conjugates, ~5% as cysteine and mercapturate conjugates.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; <5% metabolized via CYP enzymes.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination